{
    "nctId": "NCT00630032",
    "briefTitle": "Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer",
    "officialTitle": "Randomized, Open Label, Multicentric Phase III Evaluating the Benefit of a Sequential Regimen Associating FEC 100 and Ixabepilone in Adjuvant Treatment of Non Metastatic, Poor Prognosis Breast Cancer Defined as Triple-negative Tumor [HER2 Negative - ER Negative - PR Negative] or [HER2 Negative and PR Negative] Tumor; in Node Positive or Node Negative Patients.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 762,
    "primaryOutcomeMeasure": "Percentage of Participants With Disease-free Survival (DFS)",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\nInclusion criteria:\n\n* Histologically proven invasive unilateral breast cancer (regardless of the type)\n\n  * Initial clinical condition compatible with complete initial resection\n  * No residual macro or microscopic tumor after surgical excision\n* Node-positive disease (i.e., positive sentinel node or positive axillary clearance) (N+) or node-negative disease (-) meeting the following criteria :\n\n  * Stage II or III disease\n  * pT \\>20 mm (T1-4)\n* Patients must meet 1 of the following hormone-receptor criteria:\n\n  * Node-positive patients: triple-negative\\* tumor (HER2 negative, estrogen-receptor \\[ER\\] negative, and progesterone receptor \\[PR\\] negative) OR double-negative (HER2 negative, PR negative, and ER+)\n  * Node-negative patients: triple-negative\\* tumor only\n* NOTE: \\*Hormone-receptor negativity is defined as ER \\<10% and PR \\<10% by IHC and HER2 negativity is defined as IHC 0-1+ OR IHC 2+ and FISH or CISH negative\n* Must be able to begin chemotherapy no later than day 49 after the initial surgery\n\nExclusion criteria:\n\n* Clinically or radiologically detectable metastases (M0)\n* Bilateral breast cancer or contralateral ductal carcinoma in situ\n* Any metastatic impairment, including homolateral subclavicular node involvement, regardless of its type\n* Any tumor \u2265T4a (cutaneous invasion, deep adherence, inflammatory breast cancer)\n* HER 2 overexpression defined as IHC 3+ OR IHC 2+ and FISH or CISH positive\n* Any clinically or radiologically suspect and non-explored damage to the contralateral breast\n\nPATIENT CHARACTERISTICS:\n\nInclusion criteria:\n\n* Female\n* Pre- or postmenopausal\n* ECOG performance status 0-1\n* Peripheral neuropathy \u2264grade 1\n* Neutrophil count \u22652,000/mm\u00b3\n* Platelet count \u2265100,000/mm\u00b3\n* Hemoglobin \\>9 g/dL\n* AST and ALT \u22641.5 times upper limit of normal (ULN)\n* Alkaline phosphatase \u22642.5 times ULN\n* Total bilirubin \u22641.0 times ULN\n* Serum creatinine \u22641.5 times ULN\n* LVEF \u226550% by MUGA scan or echocardiography\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for up to 8 weeks after completion of study treatment\n\nExclusion criteria:\n\n* Previous cancer (except cutaneous baso-cellular epithelioma or uterine peripheral epithelioma) in the preceding 5 years, including invasive contralateral breast cancer\n* Patients with any other concurrent severe and/or uncontrolled medical disease or infection that could compromise participation in the study\n* Clinically significant cardiovascular disease within the past 6 months including any of the following:\n\n  * Unstable angina\n  * Congestive heart failure\n  * Uncontrolled hypertension (i.e., blood pressure \\>150/90 mm Hg)\n  * Myocardial infarction\n  * Cerebral vascular accidents\n* Known prior severe hypersensitivity reactions to agents containing Cremophor EL\n* Patients with any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule\n* Patients deprived of liberty or placed under the authority of a tutor\n\nPRIOR CONCURRENT THERAPY:\n\n* At least 2 weeks since prior minor surgery (excluding breast biopsy) and adequately recovered\n* At least 3 weeks since prior major surgery and adequately recovered\n* No prior chemotherapy, hormonal therapy, or radiotherapy\n* More than 72 hours since prior and no concurrent treatment with any of the following strong inhibitors of CYP3A4:\n\n  * Amiodarone\n  * Clarithromycin\n  * Amprenavir\n  * Delavirdine\n  * Voriconazole\n  * Erythromycin\n  * Fluconazole\n  * Itraconazole\n  * Ketoconazole\n  * Indinavir\n  * Nelfinavir\n  * Ritonavir\n  * Saquinavir\n* No concurrent participation in another therapeutic trial involving an experimental drug",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}